Trends in pharmacological therapy following an acute coronary syndrome in Portugal: A systematic review

Journal of Cardiovascular Medicine

Volumn 17, Issue 9, 2016, Pages 639-646

  Pereira, Marta ^a   Lopes Conceição, Luisa ^a   Bennett, Kathleen ^b   Dias, Paula ^c   Laszczynska, Olga ^a   Lunet, Nuno ^a   Azevedo, Ana ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b ST JAMES S HOSPITAL   (Ireland)

^c Centro Hospitalar Universitário de São João   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; DRUG MONITORING; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; PHARMACEUTICAL CARE; PORTUGAL; PRESCRIPTION; REVIEW; SECONDARY PREVENTION; SEX RATIO; SYSTEMATIC REVIEW; TIME TO TREATMENT; ANALOGS AND DERIVATIVES; PROCEDURES;

ACUTE CORONARY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIOVASCULAR AGENTS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SECONDARY PREVENTION; TICLOPIDINE;

EID: 84981234061     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000258     Document Type: Review

References (49)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-2139.
2. Steg G, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-2619.
3. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
4. Van De Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
5. Levi F, Lucchini F, Negri E, et al. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002;88:119-124.
6. Levi F, Chatenoud L, Bertuccio P, et al. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil 2009;16:333-350.
7. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-1107.
8. Palmieri L, Bennett K, Giampaoli S, et al. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010;100:684-692.
9. Flores-Mateo G, Grau M, O'Flaherty M, et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988-2005. Rev Esp Cardiol 2011;64:988-996.
10. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-137.
11. Fernando PB, Ferreira A, Dias P, et al. Pharmacologic treatment of acute myocardial infarction: 2 large clinical trials at a central hospital. Rev Port Cardiol 1996;15:617-630; 611.
12. Caires G, Pereira D, Freitas AD, et al. Thrombolytic therapy impact on prognosis after twelve months of first acute myocardial infarction. Rev Port Cardiol 2000;19:1103-1119.
13. Bettencourt P, Ferreira A, Pardal-Oliveira N, et al. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 2000;23:921-927.
14. Teles R, Ferreira J, Aguiar C, et al. Prognostic value of cardiac troponin I release kinetics in unstable angina. Rev Port Cardiol 2000;19:407-422.
15. Morais J, Ferreira D, Soares R, et al. Management of acute myocardial infarction in Portugal. Results of a nationwide survey. Rev Port Cardiol 2001;20:709-722.
16. Timoteo AT, Fiarresga A, Feliciano J, et al. Importance of complex additional stenosis after primary angioplasty for acute myocardial infarction in medium-term prognosis. Rev Port Cardiol 2004;23:853-864.
17. Adao L, Santos L, Bettencourt N, et al. Acute coronary syndromes in young women. Rev Port Cardiol 2004;23:69-77.
18. Fiarresga AJ, Ferreira RC, Feliciano J, et al. A systematic invasive strategy in non-ST elevation acute coronary syndromes: is age a limiting factor? Rev Port Cardiol 2005;24:11-20.
19. Timoteo AT, Fiarresga A, Feliciano J, et al. Impact of combination medical therapy on mortality in patients with acute coronary syndromes. Rev Port Cardiol 2006;25:1109-1118.
20. Sampaio F, Mateus P, Bettencourt N, et al. Determinants of left ventricular systolic function recovery after an acute coronary syndrome. Rev Port Cardiol 2006;25:321-327.
21. Lopes LR, Joao I, Vinhas H, et al. Evaluation of systolic and systo-diastolic function: the Tei index in acute myocardial infarction treated with acute reperfusion therapy - early and late evaluation. Rev Port Cardiol 2007;26:649-656.
22. Pereira H, Da Silva PC, Goncalves L, et al. Elective and primary angioplasty at hospitals without on-site surgery versus with on-site surgery: results from a national registry. Rev Port Cardiol 2008;27:769-782.
23. Nabais S, Rocha S, Joao C, et al. Prognostic impact of moderate renal dysfunction in acute coronary syndromes. Rev Port Cardiol 2008;27:303-312; discussion 315-307.
24. Timoteo AT, Fiarresga A, Feliciano J, et al. Adherence to guidelines in the treatment of acute coronary syndromes: progress over time. Rev Port Cardiol 2008;27:803-812.
25. Santos JF, Aguiar C, Gavina C, et al. Portuguese Registry of Acute Coronary Syndromes: seven years of activity. Rev Port Cardiol 2009;28:1465-1500.
26. Gaspar A, Nabalis S, Rocha S, et al. Smoking in acute coronary syndromes: the 'smoker's paradox' revisited. Rev Port Cardiol 2009;28:425-437.
27. Teixeira R, Lourenco C, Baptista R, et al. Invasive versus conservative strategy in nonsT elevation acute coronary syndromes: data from a single Portuguese center. Rev Port Cardiol 2009;28:355-373.
28. Raposo L, Aguiar C, Ferreira J, et al. Myocardial revascularization reverses adverse outcome in non-ST-elevation acute coronary syndromes complicated by heart failure. Rev Port Cardiol 2010;29:1131-1142.
29. Saraiva F, Antonio N, Lourenco C, et al. Heart rate and prognosis in acute coronary syndromes. Rev Port Cardiol 2010;29:1101-1119.
30. Teixeira M, Sa I, Mendes JS, et al. Acute coronary syndrome in young adults. Rev Port Cardiol 2010;29:947-955.
31. Cale R, Ferreira J, Aguiar C, et al. Diagnosis of myocardial infarction using the new universal definition: is it enough for risk stratification and guiding decision for revascularization? Acute Card Care 2010;12:130-137.
32. Timoteo AT, Toste A, Ramos R, et al. Admission heart rate as a predictor of mortality in patients with acute coronary syndromes. Acute Card Care 2011;13:205-210.
33. Picarra BC, Santos AR, Celeiro M, et al. Noncardiac comorbidities in the very elderly with acute myocardial infarction: prevalence and influence on management and in-hospital mortality. Rev Port Cardiol 2011;30:379-392.
34. Rocha A, Araujo V, Parada F, et al. Age does not determine the physical, functional and psychosocial response to a cardiac rehabilitation program. Rev Port Cardiol 2011;30:479-507.
35. Carmo P, Ferreira J, Aguiar C, et al. Does continuous ST-segment monitoring add prognostic information to the TIMI, PURSUIT, and GRACE risk scores? Ann Noninvasive Electrocardiol 2011;16:239-249.
36. Kotseva K, on behalf of the EUROASPIRE Study Group. Lessons from EUROASPIRE I, II, and III surveys. Heart Metab 2011;50:32-35.
37. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989;80:749-756.
38. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
39. A randomized trial of propranolol in patients with acute myocardial, infarction. I. Mortality results. JAMA 1982;247:1707-1714.
40. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
41. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother 1993;27:755-766.
42. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
44. Rockson SG, De Goma EM, Fonarow GC. Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. Cardiovasc Drugs Ther 2007;21:375-388.
45. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001;103:2768-2770.
46. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-1158.
47. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243.
48. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007;154:1108-1115.
49. Bagnall AJ, Yan AT, Yan RT, et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010;3:530-537.